A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Clinical Trial

Official title:
An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Status Completed

Clinical Trial Summary

The purpose of the study is to assess long-term safety and tolerability of weekly doses of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Polyradiculoneuropathy
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Clinical Trial Details

NCT number	NCT04051944
Study type	Interventional
Source	UCB Pharma
Contact
Status	Completed
Phase	Phase 2
Start date	August 21, 2019
Completion date	November 10, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05363358` - A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Completed	`NCT03864185` - The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies	Phase 2
Completed	`NCT03861481` - A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy	Phase 2
Active, not recruiting	`NCT05084053` - A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)	Phase 3